Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LU-TARGET: A Phase 1 Study of Lutetium-177-PSMA-617 Adjuvant Radiotherapy for IDH Wild Type Gliomas Expressing PSMA Following Standard Treatment

NCT07223034 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT07223034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07223034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LU-TARGET: A Phase 1 Study of Lutetium-177-PSMA-617 Adjuvant Radiotherapy for IDH Wild Type Gliomas Expressing PSMA Following Standard Treatment
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
October 27, 2025
Completion date
October 31, 2027
Enrollment
20 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse astrocytoma, idh-wildtype (grade 2-4), diffuse hemispheric glioma, h3 g34-mutant, diffuse midline glioma, h3 k27-altered, diffuse pediatric-type high-grade glioma, h3-wildtype and idh-wildtype, glioblastoma, idh-wildtype, glioma